Russell Scott

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Lesley Burgess, Russell Scott, Rob Scott, 2015, The Lancet.

RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts

S. Melquist, J. Knowles, D. Gaudet, 2023, Nature Medicine.

A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis.

B. Neuschwander‐Tetri, K. Cusi, M. Yuen, 2022, Journal of hepatology.

RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia

S. Melquist, J. Knowles, P. Clifton, 2020 .

RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia.

C. Ballantyne, S. Thackwray, Ting Chang, 2023, NEJM evidence.